The Opening of a new Office for Open Innovation in the Boston Area

Kissei Pharmaceutical Co., Ltd. (Head Office: Matsumoto, Nagano, Japan; Chairman and CEO: Mutsuo Kanzawa; "Kissei") announces that today our U.S. subsidiary KISSEI AMERICA, INC. (Head Office: Fort Lee, New Jersey; President: Osamu Nakanishi) opened a new office, the Boston Open Innovation Office ("BOIO"), in the Boston area of Massachusetts, U.S.A., as a hub for promoting open innovation in drug discovery research.

The Boston area is home to some of the world's leading universities, research institutions, and venture companies, forming an ecosystem in the life sciences field that is constantly generating core innovations in drug discovery. By establishing BOIO as our hub, we aim to increase access to advanced research technologies and seeds, promote open innovation, and strengthen our drug discovery platform for the creation of innovative drugs.

"Since our founding, we have been committed to the research and development of new drugs under the belief that 'a pharmaceutical company cannot exist without R&D.' By opening BOIO in the center of one of the world's leading ecosystems, we aim to gather information on innovation and promote collaboration with external partners to create original pharmaceutical products." said Mutsuo Kanzawa, CEO of Kissei.

As an R&D-oriented pharmaceutical company, we will continue to strive for sustainable growth and the creation of innovative new drugs.

Locations

《Reference》

About KISSEI AMERICA, INC.
Based in Fort Lee, New Jersey, USA, KISSEI AMERICA, INC. is a wholly owned subsidiary of Kissei Pharmaceutical Co., Ltd.. The company was established in 1997 as KISSEI U.S.A., INC. and changed to its current name in 2004. The company's main function is business development activities in the U.S. and Europe.